Targeted drug with or without radiation for HER2-positive breast cancer brain tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether adding radiation therapy to a targeted cancer drug (trastuzumab rezetecan) is better than the drug alone for women with HER2-positive breast cancer that has spread to the brain. If you have untreated brain tumors from this type of breast cancer, this study aims to find the best way to stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have HER2-positive breast cancer that has spread to other parts of the body and at least one brain tumor that hasn't been treated with radiation.
- You have not yet had radiation to the brain, or you choose not to have it, and you don't need immediate surgery for brain complications.
- You have never been treated with trastuzumab deruxtecan (Enhertu) or a similar drug called an antibody drug conjugate.
- You do not have serious lung disease or unstable heart problems, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (Enhertu) with precise radiation (SRS) for people whose HER2-positive breast cancer has spread to the brain. It aims to see if this combo is safe and effective for treating brain metastases.
This trial tests a new targeted drug called trastuzumab rezetecan (T-DXh) for patients with HER2-positive breast cancer who didn't have a complete response to standard chemotherapy and targeted drugs. The goal is to see if this new drug can help shrink remaining cancer.
This study is looking at how well the drug trastuzumab deruxtecan (Enhertu) works for women and men with HER2-positive breast cancer that has spread to the brain. Researchers want to see how much of the drug gets into the spinal fluid and if it helps shrink brain tumors.
This trial tests a new drug, trastuzumab rezetecan, for women with breast cancer that has come back or spread and cannot be removed by surgery. It's for those who haven't had chemotherapy for advanced disease but have tried hormone therapy and it stopped working.
This study tests a new drug (trastuzumab rezetecan) for advanced solid tumors that have a protein called HER2 on their surface. The drug combines an antibody that targets HER2 with a chemotherapy component. It's designed for cancers that have grown despite prior treatment or have no good alternatives.
This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.
Hear when a new HER2-positive Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.